Targeting Oncogenic KRAS-G12D Mutation Employing Engineered Exosomes in Pancreatic Cancer

Time: 9:25 am
day: Day One


  • Direct inhibitors do not exist for KRAS-G12D
  • We engineered exosomes to deliver siRNA specific to Kras-G12D (iExosomes)
  • The iExosomes target pancreatic cancer cells to suppress tumor growth and increase the overall survival of mice with PDAC
  • Preclinical studies, GLP-toxicology studies, clinical grade GMP production and FDA IND filing led to a Phase I clinical trial in PDAC